Literature DB >> 24307720

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Lisa K Hicks1, Harriet Bering, Kenneth R Carson, Judith Kleinerman, Vishal Kukreti, Alice Ma, Brigitta U Mueller, Sarah H O'Brien, Marcelo Pasquini, Ravindra Sarode, Lawrence Solberg, Adam E Haynes, Mark A Crowther.   

Abstract

Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.

Entities:  

Mesh:

Year:  2013        PMID: 24307720     DOI: 10.1182/blood-2013-07-518423

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Ionizing radiation exposure as a result of diagnostic imaging in patients with lymphoma.

Authors:  M P Crowley; S B O'Neill; B Kevane; D C O'Neill; J A Eustace; M R Cahill; B Bird; M M Maher; K O'Regan; D O'Shea
Journal:  Clin Transl Oncol       Date:  2015-08-26       Impact factor: 3.405

Review 2.  Thrombophilia: clinical-practical aspects.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Pseudo-Wellens' syndrome in pulmonary embolism.

Authors:  Yub Raj Sedhai; Soney Basnyat; Priyanka T Bhattacharya
Journal:  BMJ Case Rep       Date:  2018-12-19

4.  Perioperative management of antithrombotic and antiplatelet therapy.

Authors:  Arthur W Bracey
Journal:  Tex Heart Inst J       Date:  2015-06-01

5.  Implementation of an institutional protocol to improve inferior vena cava utilization and outcomes.

Authors:  Amihai Rottenstreich; Ariela Arad; Naama Lev Cohain; Allan I Bloom; David Varon; Alexander Klimov; Batia Roth; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

Review 6.  Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.

Authors:  Jonathon B Cohen; Madhusmita Behera; Carrie A Thompson; Christopher R Flowers
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

7.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04

8.  Searching for Evidence-Based Reassurance Where None Could Be Found.

Authors:  Rozalina G McCoy
Journal:  J Clin Oncol       Date:  2018-02-01       Impact factor: 44.544

9.  Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.

Authors:  Maurizio Margaglione; Emilia Antonucci; Giovanna D'Andrea; Ludovica Migliaccio; Walter Ageno; Eugenio Bucherini; Benilde Cosmi; Anna Falanga; Giuliana Martini; Daniela Mastroiacovo; Carmelo Paparo; Daniela Poli; Sophie Testa; Gualtiero Palareti
Journal:  Blood Transfus       Date:  2020-09-18       Impact factor: 3.443

Review 10.  Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.

Authors:  Mary Kwok; S Peter Wu; Clifton Mo; Thomas Summers; Mark Roschewski
Journal:  Curr Treat Options Oncol       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.